

**A fluoride-responsive genetic circuit enables *in vivo* biofluorination in engineered
*Pseudomonas putida***

Calero *et al.*

Supplementary Table 1. Bacterial strains and plasmids used in this study.

Strains	Relevant characteristics ^a	Reference
<i>E. coli</i> DH5 α	Cloning host; F ⁻ λ - <i>endA1 glnX44(AS) thiE1 recA1 relA1 spoT1 gyrA96(Nal^R) rfbC1 deoR nupG Φ80(lacZΔM15) Δ(argF-lac)U169 <i>hsdR17(r_K-m_K⁺)</i></i>	Meselson and Yuan ¹
<i>P. putida</i> KT2440	Wild-type strain; derivative of <i>P. putida</i> mt-2 cured of the TOL plasmid pWW0, <i>hsdR1(r⁻ m⁺)</i>	Bagdasarian <i>et al.</i> ²
<i>P. putida</i> KT2440 Δ <i>crcB</i>	<i>P. putida</i> KT2440 derivative, in-frame deletion of <i>crcB</i> (PP_4001)	This study
<i>P. putida</i> KT2440 ::FRS-T7RNAP	<i>P. putida</i> KT2440 derivative, mini-Tn7 module with the gene encoding T7 RNA polymerase under control of FRS integrated after <i>glmS</i> (PP_5409)	This study
<i>P. putida</i> KT2440 Δ <i>crcB</i> ::FRS-T7RNAP	<i>P. putida</i> KT2440 Δ <i>crcB</i> derivative, mini-Tn7 module with the gene encoding T7 RNA polymerase under control of FRS integrated after <i>glmS</i> (PP_5409)	This study
Plasmids	Relevant characteristics	Reference
pSEVA441	Cloning vector; <i>oriV</i> (pRO1600/ColE1); Str ^R	Silva-Rocha <i>et al.</i> ³
pS441-FRSv1	Derivative of vector pSEVA441, FRSv1 \rightarrow <i>msfGFP</i> ; Str ^R	This study
pS441-FRSv2	Derivative of vector pSEVA441, FRSv2 \rightarrow <i>msfGFP</i> ; Str ^R	This study
pS441-FRSv3	Derivative of vector pSEVA441, FRSv3 \rightarrow <i>msfGFP</i> ; Str ^R	This study
pS441-FRSv4	Derivative of vector pSEVA441, FRSv4 \rightarrow <i>msfGFP</i> ; Str ^R	This study
pTn7-M	Tn7 integration vector; <i>oriV</i> (R6K); Gm ^R Km ^R	Choi <i>et al.</i> ⁴
pTn7::FRS-T7RNAP	Delivery plasmid for mini-Tn7[FRSv1 \rightarrow T7RNAP] integration; Gm ^R Km ^R	This study
pTNS2	Helper plasmid for constitutive expression of <i>tnsABCD</i> encoding the Tn7 transposase; <i>oriV</i> (R6K); Amp ^R	Choi <i>et al.</i> ⁴
pPS23	ProUSER expression vector; <i>xyIS/Pm</i> , USER cassette; Km ^R	Calero <i>et al.</i> ⁵
pFB-2F1	Derivative of vector pPS23, <i>xyIS/Pm</i> \rightarrow <i>flA1</i> ; Km ^R	This study
pFB-2F2	Derivative of vector pPS23, <i>xyIS/Pm</i> \rightarrow <i>SxflA</i> ; Km ^R	This study
pSEVA231	Cloning vector; <i>oriV</i> (pBBR1); Km ^R	Silva-Rocha <i>et al.</i> ³
pS231T7	Derivative of vector pSEVA231 containing the T7 promoter; Km ^R	Volke <i>et al.</i> ⁶
pFB-1F1	Derivative of vector pS231T7; <i>P</i> _{T7} \rightarrow <i>flA1</i> ; Km ^R	This study
pFB-1F2	Derivative of vector pS231T7; <i>P</i> _{T7} \rightarrow <i>SxflA</i> ; Km ^R	This study
pFB-1F1P ^{H1}	Derivative of vector pS231T7; <i>P</i> _{T7} \rightarrow <i>flA1-NHisflB1</i> ; Km ^R	This study
pFB-1F2P ^{H2}	Derivative of vector pS231T7; <i>P</i> _{T7} \rightarrow <i>SxflA-NHisSxflB</i> ; Km ^R	This study
pFB-1F2P ^{H1}	Derivative of vector pS231T7; <i>P</i> _{T7} \rightarrow <i>SxflA-NHisflB1</i> ; Km ^R	This study
pFB-2F21P ^{H1}	Derivative of vector pPS23, <i>xyIS/Pm</i> \rightarrow <i>flA1-NHisflB1</i> ; Km ^R	This study
pFB-2F2P2	Derivative of vector pPS23, <i>xyIS/Pm</i> \rightarrow <i>SxflA-SxflB</i> ; Km ^R	This study
pS231T7::msfGFP	Derivative of vector pS231T7; <i>P</i> _{T7} \rightarrow <i>msfGFP</i> ; Km ^R	This study
pSEVA231-CRISPR	Helper plasmid for genome engineering; <i>oriV</i> (pBBR1); CRISPR array; Km ^R	Aparicio <i>et al.</i> ⁷
pSEVA231-CRISPR:: <i>crcB</i>	Derivative of vector pS231-CRISPR with a target region for <i>crcB</i>	This study
pSEVA658- <i>ssr</i>	Helper plasmid for genome engineering; <i>xyIS/Pm</i> \rightarrow <i>ssr</i> ; <i>oriV</i> (RFS1010); Gm ^R	Aparicio <i>et al.</i> ⁷
pSEVA421-Cas9tr	Helper plasmid for genome engineering; <i>cas9</i> ; <i>oriV</i> (RK2); Str ^R	Aparicio <i>et al.</i> ⁷

^a FRS, fluoride-responsive riboswitch; Antibiotic markers: Amp, ampicillin; Gm, gentamicin; Km, kanamycin; Nal, nalidixic acid; and Str, streptomycin.

Supplementary Table 2. Oligonucleotides used in this study.


Name	Sequence (5'→3')	Purpose
<i>flA1_F_AvrII</i>	TCGACCTAGGAGGAGGAAAAACATATGGCC	<i>flA1</i> amplification for cloning using <i>AvrII</i> and <i>EcoRI</i> sites
<i>flA1_R_EcoRI</i>	TCGAGAATTCTCAACGGGCCTCC	
<i>SxinflA*-U-F</i>	AGGCGAUAGGAGGAGGAAAAACATATGTCCGCCG	<i>SxinflA</i> amplification for USER cloning in pPS23
<i>SxinflA*-U-R</i>	AGGTGCGAUTCAGTTGGTTTCAACGCGCACCTTGAG	
<i>PT7SxinflA_U_F</i>	ATCCTCUAGGAGGAGGAAAAACATATGTCCGCCG	<i>SxinflA</i> amplification for USER cloning in pS231T7
<i>PT7SxinflA_U_R</i>	AGCTTGCAUTCAGTTGGTTTCAACGCGCACCTTGAG	
<i>flB1NHis-U-F</i>	ATGCAAGCUAGGAGGAGGAAAAACATATGCATCATCACC	USER primers to clone <i>flB1</i> -NHis into pFB-PT7 <i>flA1</i>
<i>flB1-U-R</i>	AGGCGAUTCACACGACCGGGGCGATG	
<i>pSEVA_U_flB</i>	ATCGCCUTGCGGCCGCGTCGTGACTG	USER primers to amplify vector pFB-PT7 <i>flA1</i>
<i>flA1_RSv1_U_R</i>	AGCTTGCAUTCACGCGGCTCCACGCGC	
<i>SxflB-Histag-F</i>	ACATGCAUCATCACCACCACCATAGAGAAACCAGAGGCG CAGCATTCC	<i>SxflB</i> -NHis amplification for USER cloning in pFB-PT7 <i>SxflA</i>
<i>SxflB-Histag-R</i>	ATGCATGUGTTTTTCTCTCTCTCGAGGAA	
<i>pTn7-U-R</i>	AGAGGAUTTAATTAAGACGTCTTGACATAAGCC	USER primers to amplify backbone pTn7-M
<i>pTn7-U-F</i>	ACGACCUAACACGATTAACATCGCTAAGAAC	
<i>PsyProm_U_F</i>	ATCCTCUTTTGGCCCTCTTTCGTAAG	USER primer to amplify FRSv1 and FRSv2
<i>Rib_EriC_U_R</i>	ACTAGGUCGTCGAAATTTAGACATT	USER primer to amplify FRS1 and FRSv3
<i>PEM7_U_F</i>	ATCCTCUTTGTGACAATTAATCATCG	USER primer to amplify FRSv3 and FRSv4
<i>Rib_ATG_U_R</i>	ACTCATUTGGCCAGCCACAAAAATAAG	USER primer to amplify FRSv2 and FRSv4
<i>GFPEriC_U_F</i>	ACCTAGUAAAGGAGAAGAACTTTTC	USER primer to amplify <i>msfGFP</i> in FRSv1 and FRSv3
<i>GFP_ATG_U_F</i>	AATGAGUAAAGGAGAAGAACTTTTC	USER primer to amplify <i>msfGFP</i> in FRSv2 and FRSv4
<i>GFP_U_R</i>	AGCTTGCAUCTATTTGTATAGTTCATCC	USER primer to amplify <i>msfGFP</i>
<i>pSEVA_U_F</i>	ATGCAAGCUTGCGGCCGCGTC	USER primers to amplify pSEVA441 and pS231T7
<i>pSEVA_U_R</i>	AGAGGAUCCCCGGGTACCGAGC	
<i>RSv1-T7RNAPol-U-R</i>	AGGTCGUCGAAATTTAGACATTTGG	USER primer to amplify FRSv1
<i>crcB-CRISPR</i>	AAACTTTCCATCAGGCGCACGGTATCGAGCGAGAG	Primers for gRNA synthesis and cloning into pSEVA231-CRISPR
<i>crcB-CRISPR-R</i>	AAAACCTCTCGCTCGATACCGTGCCTGATGGAAA	
<i>crcBdel-Rec</i>	GGAATCGAGCATATCGTTCTCTCGTTATATGTAGGTGTTG GTTACATGGTTTTCTCCGCTGGCGGGGCTGTTGCGGT CGAGGTCAGCC	Recombineering oligo for <i>crcB</i> deletion in strain KT2440

Supplementary Table 3. Transitions and optimized parameters for fluorometabolites detection by mass spectrometry.^a

Compound	Parent ion	Parent mass (m/z)	Probable product formula (Hill notation)	Product mass (m/z)	DP (V)	EP (V)	CE (V)	CXP (V)	RT (min)
5'-FDA	C ₁₀ H ₁₁ FN ₅ O ₃ ⁻	269	C ₅ H ₇ FO ₃ ⁻	134	-65	-10	-64	-21	2.43
	C ₁₀ H ₁₁ FN ₅ O ₃ ⁻	269	C ₄ H ₈ FO ₂ ⁻	107	-65	-10	-14	-19	2.43
5'-FDRP	C ₅ H ₉ FO ₇ P ⁻	231	HPO ₃ ⁻	79	-40	-10	-24	-7	7.5
	C ₅ H ₉ FO ₇ P ⁻	231	C ₅ H ₇ FO ₆ P ⁻	213	-40	-10	-52	-15	7.5

^a 5'-FDA, 5'-fluoro-5'-deoxyadenosine; 5'-FDRP, 5'-fluoro-5'-deoxy-D-ribose 1-phosphate; DP, declustering potential; EP, entrance potential; CE, collision energy; CXP, collision exit potential; RT, retention time.


Supplementary Table 4. NMR characterization of chemically-synthesized 5'-fluoro-5'-deoxyadenosine.^a

5'-Fluoro-5'-deoxyadenosine (5'-FDA)						
Atom	δ (¹ H)	Int., Mult., J (Hz)	δ (¹³ C) [Mult., J (Hz)]	δ_N (¹⁵ N)	δ (¹⁹ F) [Mult., J (Hz)]	
1'	6.08	1, d, 5.1	87.4	–	–	
2'	4.74	1, m	73.9	–	–	
3'	4.54	1, m	69.4	–	–	
4'	4.39	1, dm, 29	83.2 (d, 38)	–	–	
5'	4.76	2, m	82.5 (d, 165)	–	–231 (td, 48;29)	
1	–	–	–	–	–	
2	8.25	1, s	151	–	–	
3	–	–	–	219.2 ^b	–	
4	–	–	149	–	–	
5	–	–	118.7	–	–	
6	–	–	155.5	–	–	
7	–	–	–	233.3	–	
8	8.32	1, s	140.1	–	–	
9	–	–	–	170.4	–	


^a Int., integrals; Mult., multiplicities; s, singlet; d, doublet; t, triplet; m, multiplet.

^b This assignment is unambiguous and could also be for N₁. Assignments of the NH₂ group are not possible due to exchange of the labile protons.


Note: Both 1D as well as 2D homo- and hetero-nuclear spectra were used to assign all the resonances. The ¹H and ¹⁹F chemical shifts were obtained from 1D-NMR spectra, whereas the ¹³C and ¹⁵N chemical shifts were obtained from 2D-edited heteronuclear single quantum correlation (HSQC)-, heteronuclear multiple bond correlation (HMBC)- and heteronuclear 2 bond correlation (H2BC)-spectra. The presence of ¹⁹F in the molecule enables the extraction of both one and two bond *J* coupling constants between ¹⁹F and ¹³C (¹*J*_{FC5'} and ²*J*_{FC4'}) from the HSQC spectrum as well as two and three bond *J* coupling constants between ¹⁹F and ¹H (²*J*_{FH5'} and ³*J*_{FH4'}) from the 1D-NMR spectra.




Supplementary Fig. 1. Structural organization of *FluoroBricks*. (A) The standard design followed to test different parts of the biofluorination pathway includes a defined set of synthetic biology parts; i.e. promoters, ribosome binding sites (RBS), coding sequences, His tags and transcriptional terminators. All coding sequences used in this work were codon-optimized to ensure proper expression and translation in *P. putida*. Individual transcriptional units (*FluoroBrick*) are easily composable into more complex designs by one-step *USER* cloning or restriction/ligation according to the rules of the Standard European Vector Architecture^{3,8}. (B) Nomenclature used for the plasmids containing *FluoroBricks*. Plasmids are named with the initials *FB* followed by a code of numbers and letters, standing out for the promoter and coding sequence used. An *H* superscript indicates the presence of a 6× histidine tag in the sequence.




Supplementary Fig. 2. Chemical synthesis of 5'-fluoro-5'-deoxyadenosine. The starting point was 2',3'-isopropylidene-6-chloropurine riboside [6-Chloro-9-(2,3-O-isopropylidene- β -D-ribofuranosyl)-9H-purine] (**1**), which was converted to the primary fluoride (**2**) by treatment with tosyl fluoride (TsF) and tetrabutylammonium fluoride (TBAF) in tetrahydrofuran (THF). Next, (**2**) was aminated to 2',3'-isopropylidene-5'-fluoro-5'-deoxyadenosine (**3**) with NH_3 in *tert*-butanol (*t*-BuOH). The last step, carried at room temperature (rt), was the deprotection of (**3**) with 90% (v/v) formic acid to yield 5'-fluoro-5'-deoxyadenosine. This protocol is based on the synthesis proposed by Ashton & Scammells⁹.




Supplementary Fig. 3. NMR characterization of chemically-synthesized 5'-fluoro-5'-deoxyadenosine. (A) 1D ^1H -NMR spectrum of 5'-fluoro-5'-deoxyadenosine (5'-FDA). (B) Overview ^{19}F -NMR spectrum. The large humps are background signals originating from the probe. (C) Zoom-in of the decoupled ^{19}F -NMR spectrum. (D) Zoom-in of the coupled ^{19}F -NMR spectrum.




Supplementary Fig. 4. Measurement of fluorometabolites by LC-MS/MS. (A) Chromatograms of cell-free extracts of *P. putida* KT2440 bearing plasmid pFB·1F1 (or an empty plasmid, used as a negative control), compared to the chromatogram obtained for a chemically-synthesized 5'-fluoro-5'-deoxyadenosine (5'-FDA) standard. The characteristic retention time for 5'-FDA (in min) is shown above the peak corresponding to the fluorometabolite. **(B)** Chromatograms of cell-free extracts of *P. putida* KT2440 bearing plasmid pFB·1F1PH1 (or plasmid pFB·1F1, used as a negative control), compared to the chromatogram obtained for an enzymatically-synthesized 5'-fluoro-5'-deoxy-D-ribose 1-phosphate (5'-FDRP) standard. The characteristic retention time for 5'-FDRP (in min) is shown above the peak corresponding to the fluorometabolite. Source data are provided as a Source Data file.



Supplementary Fig. 5. *In vivo* biosynthesis of 5'-fluoro-5'-deoxyadenosine in a Δ *crcB* mutant of *P. putida*. (A) Growth curves of *P. putida* KT2440 Δ *crcB*::FRS-T7RNAP containing the plasmid modules with the fluorinase of *S. xinghaiensis* (pFB-1F2, blue circles) compared to the growth of *P. putida* KT2440 Δ *crcB*::FRS-T7RNAP with an empty plasmid (gray circles). Addition of NaF at 5 mM to the cultures is indicated with a vertical black arrow (F⁻). Error bars correspond to standard deviations of three different biological replicates. (B) Intracellular concentration of 5'-FDA in the cells after 24 and 48 h of induction of the fluoride-dependent riboswitch with 5 mM NaF. CDW, cell dry weight. Data are presented as mean values and error bars correspond to standard deviations of three different biological replicates. Source data are provided as a Source Data file.



Supplementary Fig. 6. *In vitro* biosynthesis of 5'-fluoro-5'-deoxyadenosine and 5'-fluoro-5'-deoxy-D-ribose 1-phosphate. (A) Structure of plasmid constructs carrying the genes encoding fluorinases and phosphorylases from *Streptomyces* sp. MA37 (*flA1* and *flB1*) and *S. xinghaiensis* (*SxflA* and *SxflB*) under transcriptional regulation of the *XylS/Pm* expression system. *FIB1* was tagged in the *N*-terminal domain using a 6× histidine tag (NHIS); T0 and T1 indicate synthetic transcriptional terminators. (B) *In vitro* biosynthesis of 5'-fluoro-5'-deoxyadenosine (5'-FDA) and 5'-fluoro-5'-deoxy-D-ribose 1-phosphate (5'-FDRP) using cell-free extracts of *P. putida* KT2440 with selected fluorinases and phosphorylases in the configurations described in (A). Data are presented as mean values and error bars correspond to the standard deviations of three different biological replicates. Source data underlying Supplementary Figure 6b are provided as a Source Data file.



Supplementary Fig. 7. Quantification of alive and dead *P. putida* cells under biofluorination conditions.

Cultures of *P. putida* KT2440::FRS-T7RNAP bearing plasmid pFB-1F2 (encoding a fluorinase from *S. xinghaensis*) or plasmid pFB-1F2^{PH1} (encoding fluorinase and phosphorylase from *S. xinghaensis* and *Streptomyces* sp. MA37, respectively), were added or not with 15 mM NaF (indicated as +F and -F, respectively). Cells harvested from these cultures were treated with propidium iodide, and the fraction of dead cells was determined measuring fluorescence at an excitation/emission wavelength of 544/612 nm (blue bars). Growth was determined by measuring OD₆₀₀ (grey bars), and the *specific death* was determined by normalizing the fluorescence reading corresponding to dead cells to the OD₆₀₀ (orange bars). A culture of the same strain bearing an empty plasmid, added (+F) or not (-F) with NaF, was used as a control. Further controls included cultures supplemented with 15 mM NaCl (+Cl) or heated at 95°C for 5 min as indicated in the figure. Representative results from three different biological replicates are shown, and dots indicate individual measurements. Source data are provided as a Source Data file.

Supplementary References

1. Meselson, M. & Yuan, R. DNA restriction enzyme from *E. coli*. *Nature* **217**, 1110-1114 (1968).
2. Bagdasarian, M. *et al.* Specific purpose plasmid cloning vectors. II. Broad host range, high copy number, RSF1010-derived vectors, and a host-vector system for gene cloning in *Pseudomonas*. *Gene* **16**, 237-247 (1981).
3. Silva-Rocha, R. *et al.* The Standard European Vector Architecture (SEVA): a coherent platform for the analysis and deployment of complex prokaryotic phenotypes. *Nucleic Acids Res.* **41**, D666-D675 (2013).
4. Choi, K.H. *et al.* A Tn7-based broad-range bacterial cloning and expression system. *Nat. Methods* **2**, 443-448 (2005).
5. Calero, P., Jensen, S.I. & Nielsen, A.T. Broad-host-range *ProUSER* vectors enable fast characterization of inducible promoters and optimization of *p*-coumaric acid production in *Pseudomonas putida* KT2440. *ACS Synth. Biol.* **5**, 741-753 (2016).
6. Volke, D.C., Turlin, J., Mol, V. & Nikel, P.I. Physical decoupling of XylS/*P_m* regulatory elements and conditional proteolysis enable precise control of gene expression in *Pseudomonas putida*. *Microb. Biotechnol.* **13**, 222-232 (2020).
7. Aparicio, T., de Lorenzo, V. & Martínez-García, E. CRISPR/Cas9-based counterselection boosts recombineering efficiency in *Pseudomonas putida*. *Biotechnol. J.* **13**, e1700161 (2018).
8. Sánchez-Pascuala, A., de Lorenzo, V. & Nikel, P.I. Refactoring the Embden-Meyerhof-Parnas pathway as a whole of portable *GlucBricks* for implantation of glycolytic modules in Gram-negative bacteria. *ACS Synth. Biol.* **6**, 793-805 (2017).
9. Ashton, T.D. & Scammells, P.J. An improved synthesis of 5'-fluoro-5'-deoxyadenosines. *Bioorg. Med. Chem. Lett.* **15**, 3361-3363 (2005).